Dihydromorin

Dihydromorin

SCHEMBL10174295

O=C1c2c(O)cc(O)cc2OC(c2ccc(O)cc2O)C1O

nearest known ligand 0.72

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.65
CYP3A4 P08684 4/20 0.65
ALOX15 P16050 4/20 0.65
RECQL P46063 3/20 0.65
MEN1 O00255 3/20 0.65
KMT2A Q03164 3/20 0.65
HSD17B10 Q99714 3/20 0.65
SOST Q9BQB4 2/20 0.65
POLB P06746 2/20 0.65
KDM4E B2RXH2 2/20 0.65
GAA P10253 2/20 0.65
ALOX12 P18054 2/20 0.65
HIF1A Q16665 2/20 0.65
CYP1A2 P05177 1/20 0.65
NFKB1 P19838 1/20 0.65
MAPK1 P28482 1/20 0.65
TDP1 Q9NUW8 2/20 0.64
SYNJ2 O15056 1/20 0.64
APP P05067 1/20 0.64
XDH P47989 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dihydromorin SCHEMBL29397807 1.00 MAPT (0.65) MAPTCYP3A4ALOX15RECQLMEN1
Dihydromorin SCHEMBL29929436 1.00 MAPT (0.65) MAPTCYP3A4ALOX15RECQLMEN1
Dihydromorin SCHEMBL29929680 1.00 MAPT (0.65) MAPTCYP3A4ALOX15RECQLMEN1
Dihydromorin SCHEMBL6819045 1.00 MAPT (0.65) MAPTCYP3A4ALOX15RECQLMEN1
SCHEMBL15197248 0.89 MAPT (0.60) MAPTCYP3A4ALOX15RECQLMEN1
SCHEMBL27796495 0.89 MAPT (0.65) MAPTCYP3A4ALOX15RECQLMEN1
SCHEMBL3362576 0.89 MAPT (0.65) MAPTCYP3A4ALOX15RECQLMEN1
SCHEMBL15530038 0.86 SOST (0.65) MAPTCYP3A4ALOX15RECQLMEN1
SCHEMBL28841492 0.84 MAPT (0.67) MAPTCYP3A4ALOX15RECQLMEN1
SCHEMBL27222267 0.84 MAPT (0.67) MAPTCYP3A4ALOX15RECQLMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11771679-B2 Composition containing hesperetin and synergistic hypoglycemic application thereof ZHENGZHOU FRUIT RESEARCH INSTITUTE, CHINESE ACADEMY OF AGRICULTURAL SCIENCES (CN) 2023-10-03 US disclosed
US-11771679-B2 Composition containing hesperetin and synergistic hypoglycemic application thereof ZHENGZHOU FRUIT RESEARCH INSTITUTE, CHINESE ACADEMY OF AGRICULTURAL SCIENCES (CN) 2023-10-03 US disclosed
US-11753388-B2 Composition for inhibiting alpha-glucosidase and application thereof ZHENGZHOU FRUIT RESEARCH INSTITUTE, CHINESE ACADEMY OF AGRICULTURAL SCIENCES (CN) 2023-09-12 US disclosed
US-11753388-B2 Composition for inhibiting alpha-glucosidase and application thereof ZHENGZHOU FRUIT RESEARCH INSTITUTE, CHINESE ACADEMY OF AGRICULTURAL SCIENCES (CN) 2023-09-12 US disclosed
CN-111630041-B Synthesis of morin and morin derivatives 奥萨特有限公司 2023-08-15 CN disclosed
US-20230125518-A1 COMPOSITION CONTAINING HESPERETIN AND SYNERGISTIC HYPOGLYCEMIC APPLICATION THEREOF ZHENGZHOU FRUIT RESEARCH INSTITUTE, CHINESE ACADEMY OF AGRICULTURAL SCIENCES (CN) 2023-04-27 US disclosed
US-20230125518-A1 COMPOSITION CONTAINING HESPERETIN AND SYNERGISTIC HYPOGLYCEMIC APPLICATION THEREOF ZHENGZHOU FRUIT RESEARCH INSTITUTE, CHINESE ACADEMY OF AGRICULTURAL SCIENCES (CN) 2023-04-27 US disclosed
US-20230129488-A1 COMPOSITION FOR INHIBITING ALPHA-GLUCOSIDASE AND APPLICATION THEREOF ZHENGZHOU FRUIT RESEARCH INSTITUTE, CHINESE ACADEMY OF AGRICULTURAL SCIENCES (CN) 2023-04-27 US disclosed
US-20230129488-A1 COMPOSITION FOR INHIBITING ALPHA-GLUCOSIDASE AND APPLICATION THEREOF ZHENGZHOU FRUIT RESEARCH INSTITUTE, CHINESE ACADEMY OF AGRICULTURAL SCIENCES (CN) 2023-04-27 US disclosed
EP-2603594-B1 COMPOSITIONS COMPRISING A POLYPEPTIDE HAVING CELLULOLYTIC ENHANCING ACTIVITY AND A BICYCLIC COMPOUND AND USES THEREOF NOVOZYMES INC (US) 2018-04-25 EP disclosed
US-9458483-B2 Compositions comprising a polypeptide having cellulolytic enhancing activity and a bicyclic compound and uses thereof NOVOZYMES, INC. (US) 2016-10-04 US disclosed
US-20150307908-A1 Compositions Comprising A Polypeptide Having Cellulolytic Enhancing Activity And A Bicyclic Compound And Uses Thereof UNITED STATES DEPARTMENT OF ENERGY 2015-10-29 US disclosed
US-9057086-B2 Compositions comprising a polypeptide having cellulolytic enhancing activity and a bicycle compound and uses thereof NOVOZYMES, INC. (US) 2015-06-16 US disclosed
US-20140018552-A1 USE OF COMPOUNDS ISOLATED FROM MORUS BARK DONG WHA PHARM. CO., LTD. (KR) 2014-01-16 US disclosed
US-20140018552-A1 USE OF COMPOUNDS ISOLATED FROM MORUS BARK DONG WHA PHARM. CO., LTD. (KR) 2014-01-16 US disclosed
US-20130217077-A1 Compositions Comprising A Polypeptide Having Cellulolytic Enhancing Activity And A Bicyclic Compound And Uses Thereof NOVOZYMES, INC. (US) 2013-08-22 US disclosed
WO-2012021401-A1 COMPOSITIONS COMPRISING A POLYPEPTIDE HAVING CELLULOLYTIC ENHANCING ACTIVITY AND A BICYCLIC COMPOUND AND USES THEREOF NOVOZYMES, INC. (US) 2012-02-16 WO disclosed
US-20100178282-A1 COMPOUNDS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AMYLOID ASSOCIATED DISEASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230125518-A1 COMPOSITION CONTAINING HESPERETIN AND SYNERGISTIC HYPOGLYCEMIC APPLICATION THEREOF GANAB, GANC, HES1 MAPT 4188/4885CYP3A4 248/4885ALOX15 1833/4885
US-20140018552-A1 USE OF COMPOUNDS ISOLATED FROM MORUS BARK AGER, MORF4L1, HNRNPF MAPT 2794/4885CYP3A4 3690/4885ALOX15 184/4885
US-11753388-B2 Composition for inhibiting alpha-glucosidase and application thereof GANAB, MGAM, GANC MAPT 2714/4885CYP3A4 100/4885ALOX15 3092/4885
US-20100178282-A1 COMPOUNDS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AMYLOID ASSOCIATED DISEASES APP, APBA1, BACE1 MAPT 7/4885CYP3A4 4536/4885ALOX15 2115/4885
US-11771679-B2 Composition containing hesperetin and synergistic hypoglycemic application thereof GANAB, GANC, HES1 MAPT 4188/4885CYP3A4 248/4885ALOX15 1833/4885
US-20230129488-A1 COMPOSITION FOR INHIBITING ALPHA-GLUCOSIDASE AND APPLICATION THEREOF GANAB, MGAM, GANC MAPT 2714/4885CYP3A4 100/4885ALOX15 3092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.